パーキンソン病と運動合併症の患者に対するエンタカポンのCOMT阻害:
1Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, SE1 1UL, UK. peter.jenner@kcl.ac.uk.
Journal of neural transmission (Vienna, Austria : 1996)
|September 2, 2025
まとめ
レボドーパ/エンタカポン/カルビドーパ腸ゲル (LECIG) は,レボドーパの有効性を向上させ,運動の変動を管理するために継続的な投与を提供します. 実際の証拠は,口服療法で不適正なコントロールを持つ患者のLECIGをサポートしています.
科学分野:
- 薬理学について
- 神経学
- 胃腸内科
背景:
- パーキンソン病の運動変動に対するレボドパの有効性を高める.
- これらの戦略は,レボドーパの脳への投与を安定させ,経口投与による血濃度の低値を回避し,オフタイムを短縮することを目的としています.
研究 の 目的:
- レボドーパ/エンタカポン/カルビドーパ腸ゲル (LECIG) を開発するための薬理学的根拠を説明する.
- 運動変動の管理におけるLECIGのリスク・利益プロフィールに関する証拠をレビューする.
主な方法:
- COMT阻害とエンタカポンと連続ドーパミナージック投与を組み合わせる薬理学的根拠のレビュー
- 運動制御が不良な患者のLECIGに関する実用的な証拠の分析
主要な成果:
- 周辺COMT阻害剤であるエンタカポンは,レボドパの代謝を減らし,脳の可用性を高めます.
- LECIGによるエンタカポンの連続注入は,生体利用性を改善し,効果的な濃度のためにレボドパの低用量を可能にします.
- 実際のデータは,口腔療法が不十分になったときに,LECIGの運動変動管理の有用性を支持しています.
結論:
- LECIGは,COMT抑制と継続的な投与を組み合わせた,レボドパの改善された薬理学的な進歩を表しています.
- パーキンソン病で運動の変動を経験する患者の治療を最適化するためのLECIGの役割は,証拠によって支持されています.
関連する概念動画
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
593
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
593
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
439
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.3K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
869
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
869


